Human Antibodies & Hybridomas

22-24 October 2018, Pullman Riga Old Town Hotel, Riga, Latvia

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Monday 22nd October 2018

09.00-10.20
Registration

10.20-10.30
Welcome & Opening Remarks
HAH 2018 Conference Chairman Mark Glassy
(UCSD, San Diego, California, USA)

SESSION 1:
OPENING PLENARY SESSION

Moderator: Mark Glassy
(UCSD, San Diego, California, USA)

10.30-11.15
KEYNOTE:
‘Pentapeptide, targeting amyloid proteins, attenuates chronic inflammation, autoimmunity and neurodegeneration’
David Naor
(The Lautenberg Center for General and Tumor Immunology, The Hebrew University – Hadassah Medical School, Jerusalem, Israel)

11.15-11.45
KEYNOTE:
‘New ways to use human antibodies: From intracellular targets to switchable affinity’

Stefan Dubel
(Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Braunschweig, Germany)

11.45-12.15
KEYNOTE:
‘Pre-clinical development of mAbs for Crimean Congo Hemorrhagic Fever (CCHF)’

Zachary Bornholdt
(Mapp Biopharmaceutical Inc., San Diego, California, USA)

12.15-12.45
‘Naturally occurring human immuno-modulatory IgM’
Nelson N. Teng
(Stanford University School of Medicine, Stanford, California, USA)

12.45-14.00
Lunch Break

SESSION 2:
Antibody manipulations: Immune checkpoint inhibition and affinity maturation

Moderator: Lynn MacDonald
(Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA)

14.00-14.30
‘Indentification of a PDL-1 binding fcab: A potent inhibitor of immunosuppressive signals’

Neil Brewis
(F-star Biotechnology Ltd., Babraham Research Campus, Cambridge, UK)

14.30-15.00
‘GNbAC1 a non-immunomodulatory mAb for multiple sclerosis: Promises and challenges’
Francois Curtin and Alois Lang (GeNeuro SA, Geneva, Switzerland)

15.00-15.30
‘Rational library design for antibody affinity maturation’

Richard Buick
(Fusion Antibodies Ltd., Belfast, Northern Ireland, UK)

15.30-16.00
Tea Break

SESSION 3:
Novel methodologies in antibody production

Moderator: Jim Larrick
(Panorama Research, Sunnyvale, California, USA)

16.00-16.30
‘Antibody- and complement-humanized mice’
Lynn MacDonald
(Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA)

16.30-16.50
‘Molecular determinants for pritumumab activity’
Mark Glassy
(UCSD, San Diego, California, USA)

16.50-17.20
‘Next generation technology for membrane proteins and antibody development’
Mart Ustav
(Terrence Donnelly Centre for Biomolecular Research, University of Toronto, Toronto, Ontario, Canada)

17.20-18.00
SPECIAL KEYNOTE:
‘Protecting Innovation: Therapeutic Antibodies’

Andrew T. Serafini
(Kilpatrick Townsend & Stockton LLP, Seattle, Washington, USA)

 

HAH 2018 Delegates

Login details will be supplied after you have registered for the event.


HAH 2018 Sponsors

  • Kilpatrick Townsend
  • Merck
  • F-star
  • MacroGenics
  • Fusion Antibodies
  • Mapp Biopharmaceutical
  • Arsanis Biosciences
  • Aldevron
  • InCellArt
  • Polymun Scientific
  • ModiQuest Research
  • Adimab
  • OncoZine
  • hVIVO
  • ImmunoGen
  • Morphosys
  • OMT
  • Genedata
  • UCB
  • HifiBio
  • Sutro Biopharma
  • Regeneron
  • Kadmon
  • ADC Review
  • Nascent Biotech
  • Grifols
  • Boehringer Ingelheim
  • MAB Discovery
  • Geneuro
  • Catalent Biologics

HAH 2018 Downloads

HAH 2018 Leaflet

HAH 2018 Mailing List

Name
E-mail Address
What is 3+2-1?